Skip to main content
. 2024 Jun 13;19:e05. doi: 10.15420/ecr.2024.07

Figure 4: Comparison of Rivaroxaban and Vitamin K Antagonists on the Risk of Serum Creatinine Levels Doubling Among AF Patients.

Figure 4:

(A) Entire population. (B–E) Subgroup analysis: patients with diabetes (B), patients with pre-existing kidney disease (C), the elderly (D) and the Asian population (E). VKA = vitamin K antagonist.